Donate
News + Publications
Careers
Donate
Contact
Back
Who
We Are
Board of Directors + Governance
Our Leadership
Our Team
Our Partners
Our Benefactors
Our History
Our Financials
Health Impact Reports
Our
Programs
All Programs
Accelerating Medicines Partnership® (AMP®)
Accelerating COVID-19 Therapeutic Interventions & Vaccines (ACTIV)
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Biomarkers Consortium
GeneConvene Global Collaborative
Azithromycin Prevention in Labor Use Study (A-PLUS)
Master Protocol for Treatment of Non-Small Cell Lung Cancer (Lung-MAP)
Partnership For Accelerating Cancer Therapies (PACT)
Edmond J. Safra Family Lodge
All of Us Scholars Program
Education & Training Programs
Fighting
Diseases
All Disease
Cancer
Cardiovascular
Infectious Diseases
Inflammation + Immunology
Metabolic Disorders
Neuroscience
Rare Diseases
Women’s Health
Powering
Science
Team Science Day 2024
FNIH Awards Ceremony
The Lurie Prize in Biomedical Sciences
Trailblazer Prize for Physician-Scientists
Charles A. Sanders, MD Partnership Award
The Kovler Prize for Trust in Life Science Journalism
The Deeda Blair Research Initiative for Disorders of the Brain
Research Support
Fellowships & Training
Lectures
Patient
Voices
Patient and Family Resources
Donate
Partner With Us
In Conversation with FNIH’s Dr. Courtney Silverthorn, Director of the AMP Bespoke Gene Therapy Consortium, About New Rare Disease Trial Portfolio – Xtalks Life Science Podcast Ep. 114